Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dapoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapoxetine SCHEMBL9614075 | 0.92 | KMT2A (0.59) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dapoxetine SCHEMBL30600097 | 0.90 | HTR1B (0.57) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dapoxetine SCHEMBL29488428 | 0.90 | HTR1B (0.57) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dapoxetine SCHEMBL3679561 | 0.90 | HTR1B (0.57) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dapoxetine SCHEMBL29387056 | 0.90 | HTR1B (0.57) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dapoxetine SCHEMBL3672581 | 0.90 | HTR1B (0.57) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dapoxetine SCHEMBL34479 | 0.90 | HTR1B (0.57) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dapoxetine SCHEMBL14976206 | 0.89 | CHRNB2 (0.51) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dapoxetine SCHEMBL119037 | 0.89 | HTR1B (0.56) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dapoxetine SCHEMBL9292059 | 0.89 | HTR1B (0.56) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5135947-A | Treatment of depression, eating disorders, and alcoholism | ELI LILLY AND COMPANY (US) | 1992-08-04 | — | — | US | claimed |
| EP-0288188-B1 | 1-PHENYL-3-NAPHTHALENYLOXY-PROPANAMINES | ELI LILLY AND COMPANY (US) | 1991-10-16 | — | — | EP | claimed |
| EP-0288188-A1 | 1-Phenyl-3-naphthalenyloxy-propanamines | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | claimed |
| CN-103373931-B | The industrialized process for preparing of a kind of dapoxetine and intermediate thereof | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2016-04-13 | — | — | CN | disclosed |
| CN-103373931-A | Industrial preparation method of apoxetine and intermediate of apoxetine | CHONGQING PHARM RES INST CO | 2013-10-30 | — | — | CN | disclosed |
| EP-0288188-B1 | 1-PHENYL-3-NAPHTHALENYLOXY-PROPANAMINES | ELI LILLY AND COMPANY (US) | 1991-10-16 | — | — | EP | disclosed |
| EP-0288188-A1 | 1-Phenyl-3-naphthalenyloxy-propanamines | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | disclosed |